Search

Displaying results 2571 - 2580 of 10000 in total
  1. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    Achondroplasia, the most prevalent skeletal dysplasia, is caused by a gain-of-function variant in the fibroblast growth factor receptor 3 (FGFR3), which leads to overactive downstream signaling that inhibits endochondral ossification, re...

  2. Drug

    Lutetium Lu-177 vipivotide tetraxetan

    go.drugbank.com/drugs/DB16778
    ApprovedInvestigational

    [L41280] Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate

  3. Drug

    Respiratory syncytial virus vaccine, adjuvanted

    go.drugbank.com/drugs/DB17762
    ApprovedInvestigational

    [L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380]

  4. Drug

    Ademetionine

    go.drugbank.com/drugs/DB00118
    ApprovedInvestigationalNutraceutical

    Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)

    Mixtures: HEPATAMINE %8 500 ML(SETLI), HEPATAMINE %8 500 ML(SETSIZ)
  5. Drug

    Sodium phosphate, dibasic, unspecified form

    go.drugbank.com/drugs/DB14504
    Approved

    Mixtures: Marcs Twin Pack
  6. Drug

    GTI-2040

    go.drugbank.com/drugs/DB15030
    Experimental

    GTI-2040 is under investigation in clinical trial NCT00084643 (GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors).

  7. Drug

    Cycrimine

    go.drugbank.com/drugs/DB00942
    Approved

    Cycrimine is a drug used to reduce levels of acetylcholine to return a balance with dopamine in the treatment and management of Parkinson's disease.

  8. Drug

    EA-230

    go.drugbank.com/drugs/DB19114
    Investigational

    EA-230 is under investigation in clinical trial NCT03145220 (Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)).

  9. Drug

    NADH

    go.drugbank.com/drugs/DB00157
    ApprovedNutraceutical

    NADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH, a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved i...

    Mixtures: HEPATAMINE %8 500 ML(SETLI), HEPATAMINE %8 500 ML(SETSIZ)
  10. Drug

    Ripretinib

    go.drugbank.com/drugs/DB14840
    ApprovedInvestigational

    Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.